Question explored with the scientific record
Conversation so far
- 1 Atorvastatin for 73 year old. Been on statins for 30 years. + a private exchange
- 2 Atorvastatin for 73 year old. Been on statins for 30 years. Also on BP tablets, at the time no heart issues, so preventative
- 3 How can we estimate my personal heart risk to see if benefits still fit?
Answered on this page ↓
How can we estimate my personal heart risk to see if benefits still fit?
The short version: use a validated calculator, but know it overestimates, and at 73 the tools were never built for you.
The standard tool is the 2013 ACC/AHA pooled equation, which estimates 10-year risk of heart attack, stroke, or death from heart disease [3]. Its problem is calibration: in external validation it overestimated events, with observed-to-expected ratios of 0.66 in men and 0.76 in women [3]. In plain terms, it tends to hand you a risk higher than what actually happened. The 2023 PREVENT tool replaced it and dropped race from the inputs [3]. Neither was built for people over 79, and both excluded anyone with atrial fibrillation [3].
| Input | What it needs | Caveat |
|---|---|---|
| Age, sex, race | Pooled equation inputs | Overestimates risk [3] |
| Total and HDL cholesterol | Lab values | Needs current labs |
| Systolic BP, treated? | Current reading | On BP tablets, mark treated |
| Diabetes, smoking | Yes/no | - |
| Age over 79 | Not applicable | Tool excluded this group [3] |
The calculator gives a number, not a verdict. A 10-year risk of, say, 15 in 100 means 85 in 100 avoid a hard event without any statin. The statin's relative cut then applies to that smaller absolute number, and the primary-prevention benefit shrinks with age: 26% relative in people over 70, with no significant drop in total deaths [1]. Muscle symptoms hit about 21 in 100 statin users versus 6 in 100 controls in one cohort, and risk rose with age over 60 and longer use [2].
My call: run PREVENT, not the old equation, and read the output as an upper bound, not a promise. Confidence: moderate.
Sources used 3
-
Insulin resistance as a key risk factor for cardiovascular complications in prediabetes: Early therapeutic options
Insulin resistance is presented as a key early driver of cardiovascular risk in prediabetes, and the review argues that early lifestyle and metformin-based intervention can reduce progression to diabetes and mortality.
DOI: 10.62751/2713-0177-2025-6-2-04 -
Prevalence and risk factors of muscle complications secondary to statins
In a prospective comparative study of 345 statin users versus 85 matched controls, muscle symptoms were reported by 21% vs 5.9% (P=0.0013), with objective weakness in 15% of symptomatic patients (3.2% of the total cohort) and not in controls, and older age, longer statin use, di…
DOI: 10.1002/mus.22205 -
ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC
This paper reviews the 2013 ACC/AHA ASCVD risk calculator (Pooled Cohort Equation) for estimating 10-year risk of hard ASCVD events, discussing its development, validation, performance, limitations (including overestimation in various populations), and clinical use in guiding st…
DOI: 10.65357/001c.154426